{
  "id": "5a7486a90384be9551000003",
  "type": "list",
  "question": "Which molecules are inhibited by anticancer drug Dovitinib?",
  "ideal_answer": "Dovitinib (TKI-258/CHIR-258) is a pan receptor tyrosine kinase (RTK) inhibitor that targets VEGFR, FGFR, PDGFR, and KIT. It is being widely tested for treatment of various cancers.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/26149476",
    "http://www.ncbi.nlm.nih.gov/pubmed/29101463",
    "http://www.ncbi.nlm.nih.gov/pubmed/28183331",
    "http://www.ncbi.nlm.nih.gov/pubmed/25683141",
    "http://www.ncbi.nlm.nih.gov/pubmed/27267856",
    "http://www.ncbi.nlm.nih.gov/pubmed/27082062",
    "http://www.ncbi.nlm.nih.gov/pubmed/28213002",
    "http://www.ncbi.nlm.nih.gov/pubmed/28714017",
    "http://www.ncbi.nlm.nih.gov/pubmed/23443805",
    "http://www.ncbi.nlm.nih.gov/pubmed/23908597",
    "http://www.ncbi.nlm.nih.gov/pubmed/26723100",
    "http://www.ncbi.nlm.nih.gov/pubmed/22180308",
    "http://www.ncbi.nlm.nih.gov/pubmed/28736761",
    "http://www.ncbi.nlm.nih.gov/pubmed/27705940",
    "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
    "http://www.ncbi.nlm.nih.gov/pubmed/27216979",
    "http://www.ncbi.nlm.nih.gov/pubmed/27315356",
    "http://www.ncbi.nlm.nih.gov/pubmed/27245147",
    "http://www.ncbi.nlm.nih.gov/pubmed/28377480",
    "http://www.ncbi.nlm.nih.gov/pubmed/27100354",
    "http://www.ncbi.nlm.nih.gov/pubmed/27025387",
    "http://www.ncbi.nlm.nih.gov/pubmed/28342996"
  ],
  "snippets": [
    {
      "text": "Dovitinib, a potent FGFR inhibitor, has demonstrated antitumor activity in heavily pretreated patients with FGFR pathway-amplified breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28183331",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dovitinib inhibits multiple tyrosine receptor kinases, predominantly the vascular endothelial growth factor receptors (VEGFR), but also FGFRs, and could be active in MPM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28213002",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dovitinib (TKI-258/CHIR-258) is a pan receptor tyrosine kinase (RTK) inhibitor that targets VEGFR, FGFR, PDGFR, and KIT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28342996",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dovitinib, a suppressor of FGFR activity, may be active in ACC.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28377480",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We tested dovitinib, an inhibitor of both FGF and VEGF receptors, in patients progressing on anti-VEGF treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28736761",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Five HNSCC cell lines were characterized based on VEGFR1-3 and FGFR1-4 expression by sqRT-PCR and treated with three different tyrosine kinase inhibitors (TKIs) (nintedanib, dovitinib and pazopanib), all of which are effective against VEGFR and FGFR family members.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28714017",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1-3, FGFR 1-3, and PDGFR. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29101463",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ".RESULTS: Four trials involving the selective VEGFR inhibitors axitinib, tivozanib and dovitinib were analysed, all using sorafenib as the comparator. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26723100",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Dovitinib (TKI258) is an oral multi-tyrosine kinase inhibitor of FGFR, VEGFR, PDGFR \u03b2, and c-Kit. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27100354",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using this PDX model, we confirmed the ability of the FGFR inhibitors, ponatinib, dovitinib and BGJ398, to modulate FGFR signaling, inhibit cell proliferation and induce cell apoptosis in cholangiocarcinoma tumors harboring FGFR2 fusions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27216979",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition to VEGFR and PDGFR, dovitinib inhibits FGFR. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27082062",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AZD4547, BGJ398 (infigratinib), Debio-1347 and dovitinib are FGFR1/2/3 inhibitors; BLU9931 is a selective FGFR4 inhibitor; FIIN-2, JNJ-42756493, LY2874455 and ponatinib are pan-FGFR inhibitors. AZD4547, dovitinib and ponatinib are multi-kinase inhibitors targeting FGFRs, colony stimulating factor\u00a01 receptor\u00a0(CSF1R), vascular endothelial growth factor\u00a0(VEGF)R2, and others. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27245147",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In vitro, N87-TR cell lines demonstrated a higher sensitivity than did trastuzumab-sensitive parental cells to the FGFR3 inhibitor dovitinib, which reduced expression of pAKT, ZEB1, and cell migration.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267856",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The current phase 2 study evaluated the efficacy and tolerability of dovitinib, an FGFR inhibitor, in patients with advanced SCC of the lung.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27315356",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dovitinib (TKI258) is a small molecule multi-kinase inhibitor currently in clinical phase I/II/III development for the treatment of various types of cancers. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025387",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We tested various T-ALL cell lines against a small-molecule inhibitor screen of 66 compounds targeting two-thirds of the tyrosine kinome and found that combined treatment of T-ALL cells with dovitinib, an orally active multi-targeted small-molecule receptor tyrosine kinase inhibitor, and OP449 synergistically reduced the viability of all tested T-ALL cell lines. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27705940",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain mutations that confer resistance to the pan-FGFR inhibitor, dovitinib, and explore the mechanism of action of the drug-resistant mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23908597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dovitinib is a novel multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-1-3, platelet-derived growth factor receptor-\u03b2, Fms-like tyrosine kinase 3, c-Kit and fibroblast growth factor receptor-1-3.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25683141",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Dovitinib (TKI258/CHIR258) is a multi-kinase inhibitor in phase III development for the treatment of several cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION Erlotinib is a FDA approved small molecule inhibitor of epidermal growth factor receptor and dovitinib is a novel small molecule inhibitor of fibroblast growth factor and vascular endothelial growth factor receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26149476",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we explore the therapeutic potential of 2 FGFR inhibitors, the multikinase inhibitor dovitinib (TKI258) and the more selective FGFR inhibitor NVP-BGJ398 for the treatment of endometrial cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23443805",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1-3, FGFR 1-3, and PDGFR.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29101463",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The multiple kinase inhibitor dovitinib is currently under clinical investigation for hepatocellular carcinoma (HCC).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22180308",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "VEGFR, FGFR, PDGFR, KIT"
}